Avedro (NASDAQ:AVDR) Rating Increased to Buy at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Avedro (NASDAQ:AVDR) from a hold rating to a buy rating in a research report sent to investors on Monday morning, Zacks.com reports. They currently have $26.00 target price on the stock.

According to Zacks, “Avedro Inc. is a commercial-stage ophthalmic medical technology company. It focuses on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses. Avedro Inc. is based in Waltham, Massachusetts. “

Separately, Cowen cut Avedro from an outperform rating to a market perform rating and upped their price objective for the stock from $25.00 to $27.00 in a research report on Thursday, August 8th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $24.00.

NASDAQ:AVDR opened at $21.99 on Monday. The company has a quick ratio of 9.09, a current ratio of 9.90 and a debt-to-equity ratio of 0.41. The firm has a 50-day simple moving average of $19.63. Avedro has a 1 year low of $10.75 and a 1 year high of $24.74.

Hedge funds have recently bought and sold shares of the company. Gilder Gagnon Howe & Co. LLC acquired a new position in shares of Avedro during the first quarter worth about $209,000. Laurion Capital Management LP acquired a new position in shares of Avedro during the first quarter worth about $920,000. Catalyst Capital Advisors LLC acquired a new position in shares of Avedro during the first quarter worth about $31,000. Lombard Odier Asset Management USA Corp acquired a new position in shares of Avedro during the first quarter worth about $1,258,000. Finally, Redmile Group LLC acquired a new position in shares of Avedro during the first quarter worth about $1,534,000. 60.35% of the stock is owned by institutional investors.

About Avedro

Avedro, Inc, an ophthalmic pharmaceutical and medical device company, develops and commercializes products to treat ophthalmic disorders and conditions, primarily associated with corneal weakness. The company's Avedro Corneal Remodeling platform comprises KXL and Mosaic systems, which deliver ultraviolet A or UVA light, and a suite of single-use riboflavin drug formulations.

Featured Story: Stochastic Momentum Index (SMI)

Get a free copy of the Zacks research report on Avedro (AVDR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Avedro (NASDAQ:AVDR)

Receive News & Ratings for Avedro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avedro and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Insider Selling: Advanced Micro Devices, Inc.  CAO Sells $281,249.64 in Stock
Insider Selling: Advanced Micro Devices, Inc. CAO Sells $281,249.64 in Stock
Jack in the Box Inc.  CEO Sells $267,000.00 in Stock
Jack in the Box Inc. CEO Sells $267,000.00 in Stock
Insider Buying: ATCO LTD -CLASS I Common Stock   Insider Buys C$270,000.00 in Stock
Insider Buying: ATCO LTD -CLASS I Common Stock Insider Buys C$270,000.00 in Stock
Blucora  Downgraded to “Sell” at Zacks Investment Research
Blucora Downgraded to “Sell” at Zacks Investment Research
Assembly Biosciences  Cut to Hold at Zacks Investment Research
Assembly Biosciences Cut to Hold at Zacks Investment Research
Aptose Biosciences  Lowered to Hold at Zacks Investment Research
Aptose Biosciences Lowered to Hold at Zacks Investment Research


© 2006-2019 Ticker Report